Surgery for Lung Cancer: 356 Real Stories

356 stories match lung cancer and surgery. 177 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage III EGFR exon 19-deleted lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion

No sign of metastasis on PET-CT or brain MRI after 24 months of follow-up following neoadjuvant osimertinib, left upper-lobe resection, and adjuvant osimertinib.

PubMed Central
OutcomeCancer-Free / NED
Jill, who was diagnosed with Lung CancerLung Cancer

EGFR Lung Cancer: Jill's Survivor Story

Patient Info: Jill Feldman, Female, Under 40

Biomarkers: EGFR-positive

As of November 2024, Jill described living 15 years after her 2009 lung cancer diagnosis; current disease status and whether she remained on treatment were not clearly stated.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Stage 1 lung cancer found after chest injury

Patient Info: Anonymized, Female, 70+

No lung cancer recurrence and no cardiovascular events were reported 12 months after right lower lobectomy and lymph node dissection for Stage IA2 papillary lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed Central
OutcomeIn Memory
Ashley, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley Vasallo, Female, Under 40 | Stage IV

Biomarkers: No actionable driver biomarker identified; rare fusion reported

Metastatic Site: spine, hip/bone, chest cavity

As of October 2024, Ashley reported clear labs and scans after radiation for small chest-cavity and hip lesions, with scans planned every 3 months.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage I Lung Adenocarcinoma With Later Kidney Metastases Responding to Osimertinib

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; RB1 mutation; MAP3K1 mutation; PD-L1 negative

Metastatic Site: kidneys, peritoneal lymph nodes

Osimertinib produced a partial response within 6 weeks after metastatic recurrence in the kidneys. She remained alive and continued targeted treatment.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung Squamous Cell CarcinomaLung Cancer

Two Severe Kidney Injuries After Lung Cancer Immunotherapy

Patient Info: Anonymized, Male, 70+

The lung cancer remained stable without further anticancer treatment, while the patient remained dependent on hemodialysis after the second kidney injury and continued tapering prednisolone.

PubMed Central
OutcomeStable Disease / Care Ongoing
Florence, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Florence's Patient Story

Patient Info: Florence, Female, 40s | Stage IV

Metastatic Site: Brain

As of the September 2024 article update, Florence was living with metastatic lung cancer, traveling every 3 weeks for immunotherapy in a clinical trial, and reported less fatigue, more energy, and a return to sports and social life.

CancerConsult (FR)
OutcomeResponding Well
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage 1 lung adenocarcinoma: no recurrence after 2 years

Patient Info: Anonymized, Female, 50s | Stage I

No recurrence or surgical complications 2 years after uniportal video-assisted thoracoscopic left middle lobectomy and left upper-lobe wedge resection for Stage IB lung adenocarcinoma in situs inversus totalis.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

ALK-positive lung cancer spreading to both breasts after years of targeted therapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ALK-positive, ALK mutation

Metastatic Site: bilateral breasts

At age 51, about 10 years after his Stage IV diagnosis, he remained alive with stable disease 8 months after removal of bilateral breast metastases while continuing maintenance therapy.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pulmonary large cell neuroendocrine cancer treated with airway procedures and pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR negative, ALK negative, ROS1 negative, TP53 negative, PD-L1 <1%, TMB 28.3 mut/Mb

Metastatic Site: bilateral lungs

Pembrolizumab-based treatment produced a complete remission, but multiple intrapulmonary metastases recurred in October 2021 after an 18-month progression-free interval. Further local airway treatment was performed and pembrolizumab continued.

PubMed Central
OutcomeSetback / Progression
Payton, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage III Lung Adenocarcinoma: Payton's Survivor Story

Patient Info: Payton Gibbs, Female, Under 40 | Stage III

As of August 2024, Payton described herself as cancer-free after lobectomy and 4 rounds of adjuvant chemotherapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: complete resection after splenectomy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: TTF-1-positive; Synaptophysin-positive; CD56-positive

Metastatic Site: spleen

No evidence of recurrence 1 year after open splenectomy/partial diaphragm resection and later R0 resection of the primary lung tumor for Stage IVB lung cancer with splenic metastasis; systemic therapy was refused.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Primary Lung Cancer That Spread to Both Breasts and the Adrenal Gland

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: PD-L1 negative; EGFR, ALK, ROS1, RET, MET exon 14, NTRK and BRAF wild type

Metastatic Site: both breasts, subcutaneous tissue, adrenal gland

After the lung origin was established, she was in good general condition and asymptomatic while first-line systemic therapy was being planned.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Lung CancerLung Cancer

Stage 1 lung adenocarcinoma: NED after surgery alone

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: MET exon 14 skipping; PIK3CA p.; KRAS exon 2 p./D

Both independent early-stage lung adenocarcinomas were resected without lymph-node metastasis; follow-up showed normalized oncologic markers, negative lung-cancer autoantibodies, improved HRCT findings, and no recurrence for 1 year.

PubMed Central
OutcomeCancer-Free / NED